REPORTS

Let’s Pullulate and Expand Your Business

Biosimilar Therapeutic Antibodies Market - Global Professional Analysis and Forecast to 2026

Oct 18, 2019  |  155 PAGES  |  REPORT CODE: CMM216680
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Biosimilar Therapeutic Antibodies market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 14.7% during the forecast period.

This report presents the market size and development trends by detailing the Biosimilar Therapeutic Antibodies market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Biosimilar Therapeutic Antibodies market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Biosimilar Therapeutic Antibodies industry and will help you to build a panoramic view of the industrial development.

Biosimilar Therapeutic Antibodies Market, By Type:

  • Type 1

  • Type 2

  • Type 3

Biosimilar Therapeutic Antibodies Market, By Application:

  • End-Users 1

  • End-Users 2

  • End-Users 3

Some of the leading players are as follows:

  • Affitech

  • Allergan

  • AbbVie

  • Bio Farma

  • 3SBio (Shenyang Sunshine Pharmaceutical Co)

  • Affilogic

  • Daiichi Sankyo

  • Binex

  • Ablynx

  • Baliopharm

  • Bayer

  • Affimed Therapeutics

  • BiOasis Technologies

  • Baxalta

  • CytomX Therapeutics

  • AET Biotech

  • BioCND

  • Biocad

  • Affibody

  • Daewoong Pharmaceutical Co

  • AbClon

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Biosimilar Therapeutic Antibodies Market: Technology Type Analysis

  • 4.1 Biosimilar Therapeutic Antibodies Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Biosimilar Therapeutic Antibodies Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Type 1

    • 4.3.2 Type 2

    • 4.3.3 Type 3

5 Biosimilar Therapeutic Antibodies Market: Product Analysis

  • 5.1 Biosimilar Therapeutic Antibodies Product Market Share Analysis, 2018 & 2026

  • 5.2 Biosimilar Therapeutic Antibodies Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Biosimilar Therapeutic Antibodies Market: Application Analysis

  • 6.1 Biosimilar Therapeutic Antibodies Application Market Share Analysis, 2018 & 2026

  • 6.2 Biosimilar Therapeutic Antibodies Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 End-User 1

    • 6.3.2 End-User 1

    • 6.3.3 End-User 3

7 Biosimilar Therapeutic Antibodies Market: Regional Analysis

  • 7.1 Biosimilar Therapeutic Antibodies Regional Market Share Analysis, 2018 & 2026

  • 7.2 Biosimilar Therapeutic Antibodies Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Affitech

    • 9.1.1 Affitech Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Allergan

    • 9.2.1 Allergan Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 AbbVie

    • 9.3.1 AbbVie Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Bio Farma

    • 9.4.1 Bio Farma Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 3SBio (Shenyang Sunshine Pharmaceutical Co)

    • 9.5.1 3SBio (Shenyang Sunshine Pharmaceutical Co) Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 Affilogic

    • 9.6.1 Affilogic Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 Daiichi Sankyo

    • 9.7.1 Daiichi Sankyo Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Binex

    • 9.8.1 Binex Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Ablynx

    • 9.9.1 Ablynx Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Baliopharm

    • 9.10.1 Baliopharm Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Bayer

    • 9.11.1 Bayer Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Affimed Therapeutics

    • 9.12.1 Affimed Therapeutics Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 BiOasis Technologies

    • 9.13.1 BiOasis Technologies Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 Baxalta

    • 9.14.1 Baxalta Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 CytomX Therapeutics

    • 9.15.1 CytomX Therapeutics Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

  • 9.16 AET Biotech

    • 9.16.1 AET Biotech Company overview

    • 9.16.2 Financial performance

    • 9.16.3 Product benchmarking

    • 9.16.4 Strategic initiatives

    • 9.16.5 SWOT analysis

  • 9.17 BioCND

    • 9.17.1 BioCND Company overview

    • 9.17.2 Financial performance

    • 9.17.3 Product benchmarking

    • 9.17.4 Strategic initiatives

    • 9.17.5 SWOT analysis

  • 9.18 Biocad

    • 9.18.1 Biocad Company overview

    • 9.18.2 Financial performance

    • 9.18.3 Product benchmarking

    • 9.18.4 Strategic initiatives

    • 9.18.5 SWOT analysis

  • 9.19 Affibody

    • 9.19.1 Affibody Company overview

    • 9.19.2 Financial performance

    • 9.19.3 Product benchmarking

    • 9.19.4 Strategic initiatives

    • 9.19.5 SWOT analysis

  • 9.20 Daewoong Pharmaceutical Co

    • 9.20.1 Daewoong Pharmaceutical Co Company overview

    • 9.20.2 Financial performance

    • 9.20.3 Product benchmarking

    • 9.20.4 Strategic initiatives

    • 9.20.5 SWOT analysis

  • 9.21 AbClon

    • 9.21.1 AbClon Company overview

    • 9.21.2 Financial performance

    • 9.21.3 Product benchmarking

    • 9.21.4 Strategic initiatives

    • 9.21.5 SWOT analysis

 

The List of Tables and Figures (Totals 80 Figures and 128 Tables)

  • Figure Type 1 Biosimilar Therapeutic Antibodies market, 2015 - 2026 (USD Million)

  • Figure Type 2 Biosimilar Therapeutic Antibodies market, 2015 - 2026 (USD Million)

  • Figure Type 3 Biosimilar Therapeutic Antibodies market, 2015 - 2026 (USD Million)

  • Figure End-Users 1 market, 2015 - 2026 (USD Million)

  • Figure End-Users 2 market, 2015 - 2026 (USD Million)

  • Figure End-Users 3 market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Biosimilar Therapeutic Antibodies market, by country, 2015 - 2026 (USD Million)

  • Table North America Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table North America Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table North America Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table Canada Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table Canada Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Europe Biosimilar Therapeutic Antibodies market, by country, 2015 - 2026 (USD Million)

  • Table Europe Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table Europe Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table Europe Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table Germany Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table Germany Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table France Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table France Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table Italy Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table Italy Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table Spain Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table Spain Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Biosimilar Therapeutic Antibodies market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table China Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table China Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table Japan Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table Japan Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table India Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table India Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Biosimilar Therapeutic Antibodies market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table MEA Biosimilar Therapeutic Antibodies market, by country, 2015 - 2026 (USD Million)

  • Table MEA Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table MEA Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table MEA Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Biosimilar Therapeutic Antibodies market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Biosimilar Therapeutic Antibodies market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Biosimilar Therapeutic Antibodies market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Affitech Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Allergan Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AbbVie Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bio Farma Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table 3SBio (Shenyang Sunshine Pharmaceutical Co) Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Affilogic Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Daiichi Sankyo Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Binex Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Ablynx Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Baliopharm Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bayer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Affimed Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table BiOasis Technologies Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Baxalta Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table CytomX Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AET Biotech Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table BioCND Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Biocad Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Affibody Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Daewoong Pharmaceutical Co Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AbClon Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$4840
$9680
BUY NOWClick MeBUY NOW
top